RecruitingPhase 2

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

United States89 participantsStarted 2022-11-08

Plain-language summary

The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.

Who can participate

Age range18 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18-79 years
✓. Index Anterior wall STEMI
✓. Emergency coronary angiogram with primary PCI

Exclusion criteria

✕. Prior history of MI / PCI / coronary artery bypass graft (CABG) within previous 1 year
✕. Patients with previous history of left ventricular ejection fraction (LVEF) \< 40%
✕. Use of investigational drugs or devices 30 days prior to randomization
✕. Known allergy or contra-indication to gadolinium/contrast agents
✕. eGFR \< 30 ml/kg/min
✕. Any contraindication against cardiac MRI (such as metal implants)
✕. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization
✕. Body weight \> 140 kg (or 309 lbs.)

What they're measuring

Treatment Efficacy

Timeframe: 6 months

Trial details

NCT IDNCT05604131

SponsorRohan Dharmakumar

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-03-31

Contact for this trial

Clinical Research Coordinator

(317) 274-0985 csaha@iu.edu

View on ClinicalTrials.gov More Acute Myocardial Infarction Type 1 trials